Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

Cebon, J., Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators, Findlay, M., Hargreaves, C., Stockler, M., Thompson, P., Boyer, M., Roberts, S., Poon, A., Scott, A. M., Kalff, V., Garas, G., Dowling, A., Crawford, D., Ring, J., Basser, R., Strickland, A., Macdonald, G., Green, M., Nowak, A., Dickman, B., Dhillon, H. and Gebski, V. (2006) Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer, 95 7: 853-861. doi:10.1038/sj.bjc.6603325


Author Cebon, J.
Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators
Findlay, M.
Hargreaves, C.
Stockler, M.
Thompson, P.
Boyer, M.
Roberts, S.
Poon, A.
Scott, A. M.
Kalff, V.
Garas, G.
Dowling, A.
Crawford, D.
Ring, J.
Basser, R.
Strickland, A.
Macdonald, G.
Green, M.
Nowak, A.
Dickman, B.
Dhillon, H.
Gebski, V.
Title Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
Journal name British Journal of Cancer   Check publisher's open access policy
ISSN 0007-0920
1532-1827
Publication date 2006-10-03
Sub-type Article (original research)
DOI 10.1038/sj.bjc.6603325
Open Access Status DOI
Volume 95
Issue 7
Start page 853
End page 861
Total pages 9
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Language eng
Abstract Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin receptors. We aimed to determine the feasibility, safety, and activity of long-acting octreotide in advanced HCC; to identify the best method for assessing somatostatin receptor expression; to relate receptor expression to clinical outcomes; and to evaluate toxicity. Sixty-three patients with advanced HCC received intramuscular long-acting octreotide 20 mg monthly until progression or toxicity. Median age was 67 years (range 28–81 years), male 81%, Child–Pugh A 83%, and B 17%. The aetiologies of chronic liver disease were alcohol (22%), viral hepatitis (44%), and haemochromatosis (6%). Prior treatments for HCC included surgery (8%), chemotherapy (2%), local ablation (11%), and chemoembolisation (6%). One patient had an objective partial tumour response (2%, 95% CI 0–9%). Serum alpha-fetoprotein levels decreased more than 50% in four (6%). Median survival was 8 months. Thirty four of 61 patients (56%) had receptor expression detected by scintigraphy; no clear relationship with clinical outcomes was identified. There were few grade 3 or 4 toxicities: hyperglycaemia (8%), hypoglycaemia (2%), diarrhoea (5%), and anorexia (2%). Patients reported improvements in some symptoms, but no major changes in quality of life were detected. Long-acting octreotide is safe in advanced HCC. We found little evidence of anticancer activity. A definitive randomised trial would identify whether patients benefit from this treatment in other ways.
Keyword Feasibility study
Toxicity
Somatostatin,
Receptors
Scintigraphy
Octreotide
Hepatocellular carcinoma
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 38 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 40 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 05 Feb 2009, 11:23:06 EST by Maryanne Watson on behalf of Faculty Of Health Sciences